histology assessed.Conditioned medium (CM) from expanded iNPCs was administered intraperitoneally in parallel to cis-AKI mice to assess paracrine effects, and CM and iNPCs underwent mass spectrometry and RNA sequencing analyses, respectively.We generated and evaluated iNPCs functionally enhanced with reno-protective factors.Results: We developed the CFY (CHIR99021, FGF9, Y-27632) medium to enable iNPC expansion over 100-fold within two passages while maintaining NPC marker expression and renal differentiation potential in multiple iPS cell lines.Expanded iNPCs attenuated kidney injury and improved survival in cis-AKI model mice and prevented renal dysfunction, interstitial fibrosis, and senescence in AA-CKD mice.c-MET was identified as a specific surface marker, and purified c-MET + iNPCs exhibited therapeutic efficacy in both AKI and CKD.Contralateral kidneys of transplanted mice also improved, suggesting renoprotective paracrine effects.Intraperitoneal CM administration preserved renal function and survival, as analysis identified multiple secreted factors, including vascular endothelial growth factor (VEGF)-A.Furthermore, we demonstrated that iNPCs with enhanced renoprotective effects are therapeutically more effective than conventional iNPCs.Conclusion: While expanded iNPCs show great promise as a cell-based therapy for AKI and CKD, functionally enhanced iNPCs may present as even stronger candidates.Developing such advanced therapies opens new avenues for treating kidney diseases.I have potential conflict of interest to disclose.I am a shareholder of Rege nephro Co., Ltd I did not use generative AI and AI-assisted technologies in the writing process.
Borbolla-Flores et al. (Wed,) studied this question.